Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits

Inclusion Criteria: * age 20\~85 * Acute period (ischemic stroke confirmation on DWI or TIA within 14 days after symptom onset) * Below 20 point of initial NIHSS score within 14 days after stroke onset and enrolment. * Confirmation of atherosclerotic or steno-occlusive stroke mechanism (proximal cerebral arteries) on CTA or MRA . * At least hemodynamically, perfusion status of a candidate is stage II or III (decrease of regional Cerebral blood flow on CBF map), moyamoya disease * If female then not of childbearing potential * Informed consent Exclusion Criteria: * Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH), arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm * Treated with a thrombolytic \<24 hours (if \>24 hours and excluded ICH then eligible) * Score \>=1 on the NIHSS item 1a * Pre-stroke mRS score \<2 * Uncontrolled hypertension(irregularity systollic BP \> 150mmHg * Previous treatment with erythropoietin * At screening: Hemoglobin \>14 g/dl, prolonged PT or PTT, serum Cr \>2.0 ,mg/dl, BUN \>40, thrombocytopenia or neutropenia as defined by the lower limit of normal for the platelet count or white blood cell count, respectively (absolute neutrophil count of \> 1800/mm3 required for participation), or \> 2 times of normal on liver function tests (SGOT, SGPT, total bilirubin)